Aaron D Tward

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation
    Julie B Sneddon
    Department of Biochemistry, Stanford University Medical Center, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 103:14842-7. 2006
  2. ncbi Distinct pathways of genomic progression to benign and malignant tumors of the liver
    Aaron D Tward
    G W Hooper Foundation and Department of Microbiology and Immunology, University of California, San Francisco, CA 94143, USA
    Proc Natl Acad Sci U S A 104:14771-6. 2007
  3. ncbi Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer
    Susie A Lee
    Department of Biopharmaceutical Sciences, University of California, San Francisco, CA 94143, USA
    Hepatology 47:1200-10. 2008
  4. ncbi Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC
    Andrei Goga
    Department of Medicine, Division of Hematology Oncology, University of California, San Francisco, San Francisco, California 94143 0552, USA
    Nat Med 13:820-7. 2007
  5. ncbi Systemic rather than local heme oxygenase-1 overexpression improves cardiac allograft outcomes in a new transgenic mouse
    Jesus A Araujo
    Division of Cardiology, University of California, Los Angeles, CA 90095, USA
    J Immunol 171:1572-80. 2003
  6. ncbi Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism
    Toby B Cole
    Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington 98195-7720, USA
    Pharmacogenet Genomics 15:589-98. 2005

Collaborators

Detail Information

Publications6

  1. ncbi Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation
    Julie B Sneddon
    Department of Biochemistry, Stanford University Medical Center, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 103:14842-7. 2006
    ..Our data suggest that BMP antagonists may be important constituents of tumor stroma, providing a favorable microenvironment for cancer cell survival and expansion in many cancers...
  2. ncbi Distinct pathways of genomic progression to benign and malignant tumors of the liver
    Aaron D Tward
    G W Hooper Foundation and Department of Microbiology and Immunology, University of California, San Francisco, CA 94143, USA
    Proc Natl Acad Sci U S A 104:14771-6. 2007
    ....
  3. ncbi Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer
    Susie A Lee
    Department of Biopharmaceutical Sciences, University of California, San Francisco, CA 94143, USA
    Hepatology 47:1200-10. 2008
    ..In addition, we demonstrate that the integration of genomic analysis and in vivo transfection is a powerful tool to identify genes that are important during hepatic carcinogenesis...
  4. ncbi Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC
    Andrei Goga
    Department of Medicine, Division of Hematology Oncology, University of California, San Francisco, San Francisco, California 94143 0552, USA
    Nat Med 13:820-7. 2007
    ..As there are no effective small-molecule inhibitors that selectively target the MYC pathway, we propose that CDK1 inhibition might therefore be useful in the treatment of human malignancies that overexpress MYC...
  5. ncbi Systemic rather than local heme oxygenase-1 overexpression improves cardiac allograft outcomes in a new transgenic mouse
    Jesus A Araujo
    Division of Cardiology, University of California, Los Angeles, CA 90095, USA
    J Immunol 171:1572-80. 2003
    ..This Tg mouse provides a valuable tool to study mechanisms by which HO-1 exerts beneficial effects in organ transplantation...
  6. ncbi Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism
    Toby B Cole
    Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington 98195-7720, USA
    Pharmacogenet Genomics 15:589-98. 2005
    ..CONCLUSION: These results indicate that individuals expressing only the PON1Q192 allele would be more sensitive to the adverse effects of CPO or CPS exposure, especially if they are expressing a low level of plasma PON1Q192...